You are here
SciCann Therapeutics reports positive pre-clinical results for proprietary CBD combination product
TORONTO, Aug. 23, 2018 (GLOBE NEWSWIRE) -- SciCann Therapeutics Inc reports today positive results of a pre-clinical efficacy study with its proprietary “Steady Stomach” CBD combination product for Inflammatory Bowel Disease (IBD), as observed in a gold standard rodent model for Ulcerative Colitis.
The “Steady Stomach” product is a patent-pending combination of Cannabidiol (CBD) together with additional synergistic factors that potentiate and activate the anti-inflammatory properties of CBD, thus making it more effective as a potential treatment for IBD disorders. All active ingredients of the “Steady Stomach” formulation are natural food-grade compounds, thus qualifying it as a CBD food supplement product. Previously completed tox studies in rodents has demonstrated very high safety profile for the combination product, without any observed adverse events.
The study demonstrated a significant 3-fold improved efficacy for the combination product, as compared to CBD alone, in reversing the deleterious effects caused by the colitis induction agent in the study model. Specifically, while the CBD alone arm achieved only a 27% improvement score as compared to the non-treated control arm, the “Steady Stomach” combination treatment arm achieved a 79% improvement score, thus almost completely alleviating the Colitis symptoms induced in the model animals.
Dr. Zohar Koren, Co-founder and CEO of SciCann Therapeutics, stated “We are highly encouraged and excited to see the positive results of this pre-clinical study. Inflammatory Bowel Disease is a prevalent and debilitating disorder, that presents a high level of unmet need for an efficient treatment that is devoid of undesirable side effects. CBD has been shown in the past to posses a mild effect of alleviating IBD symptoms and pathology, but the amplification and potentiation of these therapeutic effects by the synergistic factors that we have introduced into the “Steady Stomach” combination product, may turn out as the much-needed key to enlarging the therapeutic window of CBD and harnessing it as an efficient and safe therapy for IBD. The positive results of this pre-clinical study pave our way forward to launching a comprehensive and rigorous clinical research program with this unique product, which we are now preparing for execution, together with our strategic partner FSD Pharma, through our alliance with Mor Research Applications – the commercial arm of Clalit Healthcare services, Israel’s largest HMO and hospital network.”
About SciCann Therapeutics
SciCann Therapeutics is a Canadian-Israeli specialty pharmaceutical company, dedicated to the development and commercialization of novel and disruptive pharmaceutical products that target and modulate the endocannabinoid system. SciCann Therapeutics is active in the fields of oncology, pain management, neurodegenerative diseases and inflammatory disorders, and develops a line of proprietary products for the treatment of chosen life- threatening conditions that present a high level of unmet need.
SciCann has created a network of collaborations with leading academic centers and medical institutions in Israel in order to engage in cutting edge science and rigorous clinical studies to develop its products, while using the permissive regulatory climate in Israel for performing its R&D programs quickly and efficiently.
Dr. Zohar Koren,
Chief Executive Officer